



Neuland Laboratories Limited
11th Floor, (5th Office Level),
Phoenix IVY Building,
Plot No. 573A-III, Road No.82,
Jubilee Hills, Hyderabad-500033,
Telangana, India

Tel : 040 67611600 / 67611700
Email : neuland@neulandlabs.com
www.neulandlabs.com

April 25, 2022

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

Scrip Code: 524558

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: NEULANLAB; Series: EQ

Dear Sirs,

Sub: SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 ("SEBI Circular") in respect of Fund raising by issuance of Debt Securities by Large Entities:- Annual Disclosure

Please find enclosed herewith Annual Disclosure under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 ("SEBI Circular") in respect of Fund raising by issuance of Debt Securities by Large Entities, for the financial year ended March 31, 2022.

This is for your information and records.

Thanking You,

Yours faithfully,

For Neuland Laboratories Limited

**Sarada Bhamidipati
Company Secretary**

Encl: As Above

Annual Disclosure to be made by an entity identified as a LC^s
(To be submitted to the Stock Exchange(s) within 45 days of the end of the FY)
(Applicable from FY 2022 onwards)

April 22, 2022

1. Name of the Company : Neuland Laboratories Limited
2. CIN : L85195TG1984PLC004393
3. Report filed for FY : FY 2021-22
4. Details of the Current block (all figures in Rs crore): **Not Applicable**

S.No.	Particulars	Details
i.	2-year block period (Specify financial years)	(T), (T+1)
ii.	Incremental borrowing done in FY (T) (a)	
iii.	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	
iv.	Actual borrowing done through debt securities in FY (T) (c)	
v.	Shortfall in the borrowing through debt securities, if any, for FY (T-1) carried forward to FY (T). (d)	
vii.	Quantum of (d), which has been met from (c) (e)	
viii.	Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) {after adjusting for any shortfall in borrowing for FY (T-1) which was carried forward to FY (T)} (f) = (b) - [(c) - (e)] {If the calculated value is zero or negative, write "nil"}	

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): **Not Applicable**

S.No.	Particulars	Details
1	2-year Block period (Specify financial years)	(T-1) ,(T)
2	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}#	



^sIn cases, where an entity is not categorised as LC for FY (T), however was LC for FY (T-1), and there was a shortfall in the mandatory bond borrowing for FY (T-1), which was carried forward to FY (T), the disclosures as prescribed in this annexure shall be made by the entity for FY (T).

#(d) and (e) are same as mentioned at 4(v) and 4(vi) of this annexure.

For Neuland Laboratories Limited



Sarada Bhamidipati
 Company Secretary
 +91 40 6761 1600



Deepak Gupta
 Chief Financial Officer
 +91 40 6761 1600